Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High Risk Melanoma

The TLR7/8 agonist, Resiquimod has been used as an immune adjuvant in cancer vaccines. We evaluated the safety and immunogenicity of the cancer testis antigen NY-ESO-1 given in combination with Montanide with or without Resiquimod in high-risk melanoma patients. In Part I of the study, patients rece...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Immunol Res
Main Authors: Sabado, Rachel Lubong, Pavlick, Anna, Gnjatic, Sacha, Cruz, Crystal M., Vengco, Isabelita, Hasan, Farah, Spadaccia, Meredith, Darvishian, Farbod, Chiriboga, Luis, Holman, Rose Marie, Escalon, Juliet, Muren, Caroline, Escano, Crystal, Yepes, Ethel, Sharpe, Dunbar, Vasilakos, John P., Rolnitzsky, Linda, Goldberg, Judith, Mandeli, John, Adams, Sylvia, Jungbluth, Achim, Pan, Linda, Venhaus, Ralph, Ott, Patrick A., Bhardwaj, Nina
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4374362/
https://ncbi.nlm.nih.gov/pubmed/25633712
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-14-0202
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados